[go: up one dir, main page]

IL232022A0 - Production of heterodimeric proteins - Google Patents

Production of heterodimeric proteins

Info

Publication number
IL232022A0
IL232022A0 IL232022A IL23202214A IL232022A0 IL 232022 A0 IL232022 A0 IL 232022A0 IL 232022 A IL232022 A IL 232022A IL 23202214 A IL23202214 A IL 23202214A IL 232022 A0 IL232022 A0 IL 232022A0
Authority
IL
Israel
Prior art keywords
production
heterodimeric proteins
heterodimeric
proteins
Prior art date
Application number
IL232022A
Other languages
Hebrew (he)
Other versions
IL232022B (en
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab As filed Critical Genmab As
Publication of IL232022A0 publication Critical patent/IL232022A0/en
Publication of IL232022B publication Critical patent/IL232022B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL232022A 2011-10-27 2014-04-09 Production of heterodimeric proteins IL232022B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161552272P 2011-10-27 2011-10-27
DKPA201100826 2011-10-27
PCT/EP2012/071294 WO2013060867A2 (en) 2011-10-27 2012-10-26 Production of heterodimeric proteins

Publications (2)

Publication Number Publication Date
IL232022A0 true IL232022A0 (en) 2014-05-28
IL232022B IL232022B (en) 2021-05-31

Family

ID=48168683

Family Applications (2)

Application Number Title Priority Date Filing Date
IL232022A IL232022B (en) 2011-10-27 2014-04-09 Production of heterodimeric proteins
IL282393A IL282393B (en) 2011-10-27 2021-04-18 Production of heterodimeric proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL282393A IL282393B (en) 2011-10-27 2021-04-18 Production of heterodimeric proteins

Country Status (20)

Country Link
US (3) US10344050B2 (en)
EP (2) EP3674320A3 (en)
JP (2) JP6475017B2 (en)
KR (1) KR102049803B1 (en)
CN (3) CN104114579B (en)
AU (3) AU2012328322A1 (en)
BR (1) BR112014010023B1 (en)
DK (1) DK2771364T3 (en)
ES (1) ES2739808T3 (en)
HR (1) HRP20191337T1 (en)
HU (1) HUE044633T2 (en)
IL (2) IL232022B (en)
IN (1) IN2014CN03887A (en)
LT (1) LT2771364T (en)
PL (1) PL2771364T3 (en)
PT (1) PT2771364T (en)
RS (1) RS59166B1 (en)
SG (2) SG11201401422VA (en)
SI (1) SI2771364T1 (en)
WO (1) WO2013060867A2 (en)

Families Citing this family (285)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI671403B (en) 2005-03-31 2019-09-11 中外製藥股份有限公司 Method for controlling controlled assembly of polypeptide
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
DK3056568T3 (en) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd PROCEDURES FOR CONTROL OF THE BLOOD PHARMACOKINETICS OF ANTIBODIES
CA2681974C (en) 2007-03-29 2019-12-31 Genmab A/S Bispecific antibodies and methods for production thereof
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
KR102467302B1 (en) 2007-09-26 2022-11-14 추가이 세이야쿠 가부시키가이샤 Modified antibody constant region
EP3674317B1 (en) 2009-03-19 2024-12-11 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
JP5889181B2 (en) 2010-03-04 2016-03-22 中外製薬株式会社 Antibody constant region variants
LT2560993T (en) 2010-04-20 2024-10-10 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
JP6320753B2 (en) 2010-05-27 2018-05-09 ゲンマブ エー／エス Monoclonal antibody against HER2
CA2817964C (en) 2010-11-17 2018-06-12 Chugai Seiyaku Kabushiki Kaisha Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
WO2013004841A1 (en) * 2011-07-06 2013-01-10 Genmab A/S Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains
PT2771364T (en) * 2011-10-27 2019-09-10 Genmab As Production of heterodimeric proteins
JP6371059B2 (en) 2011-10-31 2018-08-08 中外製薬株式会社 Antigen-binding molecules with controlled association of heavy and light chains
HUE056462T2 (en) * 2011-11-04 2022-02-28 Zymeworks Inc Stable heterodimeric antibody design with mutations in the fc domain
WO2013189516A1 (en) 2012-06-18 2013-12-27 Apeiron Biologics Ag Method for treating a gd2 positive cancer
US20150239991A1 (en) * 2012-09-25 2015-08-27 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
KR102545617B1 (en) 2012-11-28 2023-06-20 자임워크스 비씨 인코포레이티드 Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
PE20151807A1 (en) * 2013-04-29 2015-12-02 Hoffmann La Roche MODIFIED ANTIBODIES OF BINDING TO HUMAN FCRN AND METHOD OF USE
JP6618893B2 (en) * 2013-04-29 2019-12-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Asymmetric antibodies with altered FC receptor binding and methods of use
JP6546162B2 (en) 2013-07-05 2019-07-17 ゲンマブ エー／エス Humanized or chimeric CD3 antibodies
EP3050896B1 (en) * 2013-09-27 2021-07-07 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
MY176522A (en) 2013-11-04 2020-08-13 Ichnos Sciences SA Production of t cell retargeting hetero-dimeric immunoglobulins
US9840566B2 (en) 2013-11-21 2017-12-12 Apeiron Biologics Ag Preparations and methods for treating a GD2 positive cancer
ES2768649T3 (en) 2013-11-21 2020-06-23 Apeiron Biologics Ag Preparations for treating a GD2 positive cancer
CA2931986A1 (en) * 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and maintained protein a-binding properties
CN110981957B (en) 2014-01-15 2024-12-24 豪夫迈·罗氏有限公司 Fc region variants with improved protein A binding
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp TIM-3 Antibody Molecules and Their Uses
PH12016501545B1 (en) 2014-03-14 2023-12-06 Immutep Sas Antibody molecules to lag-3 and uses thereof
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
CA2946503C (en) 2014-05-28 2022-11-22 Zymeworks Inc. Modified antigen binding polypeptide constructs and uses thereof
US10647777B2 (en) * 2014-05-28 2020-05-12 Genzyme Corporation Methods of controlling the formation of disulfide bonds in protein solutions
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
MX2017001011A (en) 2014-07-21 2018-05-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor.
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
US9777061B2 (en) 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
RU2744978C2 (en) 2014-07-24 2021-03-17 Дженентек, Инк. Methods for conjugation of agent with thiol group in protein comprising at least one trisulfide bond
US10329323B2 (en) 2014-07-25 2019-06-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Method for purifying antibodies using PBS
US20170209492A1 (en) 2014-07-31 2017-07-27 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
JP6919118B2 (en) 2014-08-14 2021-08-18 ノバルティス アーゲー Treatment of cancer with GFRα-4 chimeric antigen receptor
TW202140557A (en) 2014-08-19 2021-11-01 瑞士商諾華公司 Treatment of cancer using a cd123 chimeric antigen receptor
KR20210149228A (en) 2014-09-17 2021-12-08 노파르티스 아게 Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
MA40764A (en) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
CA2964367C (en) 2014-10-14 2024-01-30 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
CA2971278C (en) 2014-12-19 2023-09-19 Ablynx N.V. Cysteine linked nanobody dimers
EP3233907B1 (en) 2014-12-19 2021-03-03 Genmab A/S Rodent bispecific heterodimeric proteins
AR103173A1 (en) 2014-12-22 2017-04-19 Novarits Ag PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF ANTIBODIES IL-17
AR103172A1 (en) 2014-12-22 2017-04-19 Novartis Ag SELECTIVE REDUCTION OF CYSTEINE WASTE IN ANTIBODIES IL-17
EP3242682A1 (en) 2015-01-08 2017-11-15 Genmab A/S Bispecific antibodies against cd3 and cd20
CA2975810C (en) 2015-02-05 2025-05-13 Ablynx N.V. Nanobody dimers linked via c-terminally engineered cysteins
EP3279216A4 (en) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha PROCESS FOR THE PRODUCTION OF A POLYPEPTIDE HETERO-OLIGOMER
CN119925616A (en) 2015-04-08 2025-05-06 诺华股份有限公司 CD20 therapy, CD22 therapy, and combination therapy with CD19 chimeric antigen receptor (CAR) expressing cells
CN108472360B (en) 2015-04-10 2023-01-17 阿迪马布有限责任公司 Method for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
JP7103751B6 (en) * 2015-04-28 2022-08-15 ザイムワークス，インコーポレイテッド Modified antigen-binding polypeptide constructs and uses thereof
MX395317B (en) 2015-07-15 2025-03-25 Genmab As HUMANIZED OR CHIMERIC CLUSTER OF DIFFERENTIATION 3 (CD3) ANTIBODIES.
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
EP4378957A3 (en) 2015-07-29 2024-08-07 Novartis AG Combination therapies comprising antibody molecules to pd-1
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
DK3317301T3 (en) 2015-07-29 2021-06-28 Immutep Sas COMBINATION THERAPIES INCLUDING ANTIBODY MOLECULES AGAINST LAYER-3
GEAP202215554A (en) 2015-07-30 2022-06-10 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
SI4209499T1 (en) * 2015-08-13 2025-01-31 Amgen Inc. Charged depth filtration of antigen-binding proteins
WO2017059551A1 (en) 2015-10-08 2017-04-13 Zymeworks Inc. Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
MX2018007089A (en) 2015-12-14 2019-01-30 Macrogenics Inc Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof.
CA3007421A1 (en) 2015-12-17 2017-06-22 Novartis Ag Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
KR102833068B1 (en) 2015-12-17 2025-07-14 노파르티스 아게 Antibody molecules against PD-1 and their uses
EP3393504B1 (en) 2015-12-22 2025-09-24 Novartis AG Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
BR112018009312A8 (en) 2015-12-28 2019-02-26 Chugai Pharmaceutical Co Ltd method for promoting purification efficiency of fc region-containing polypeptide
CN105420209A (en) * 2015-12-30 2016-03-23 海口奇力制药股份有限公司 Method for preparing rhCNB dimer
US20210198368A1 (en) 2016-01-21 2021-07-01 Novartis Ag Multispecific molecules targeting cll-1
KR20180118175A (en) 2016-03-04 2018-10-30 노파르티스 아게 Cells expressing multiple chimeric antigen receptor (CAR) molecules and their uses
BR112018068363A2 (en) 2016-03-14 2019-01-15 Chugai Seiyaku Kabushiki Kaisha cell damage-inducing therapeutic drug for use in cancer therapy
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
JP7497955B6 (en) 2016-04-15 2024-07-01 ノバルティス アーゲー Compositions and methods for selective protein expression
MX2018012648A (en) 2016-04-28 2019-01-30 Chugai Pharmaceutical Co Ltd Antibody-containing preparation.
JP7106187B2 (en) 2016-05-11 2022-07-26 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ How to save the separation matrix
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
EP3455241B1 (en) 2016-05-11 2022-02-23 Cytiva BioProcess R&D AB Method of cleaning and/or sanitizing a separation matrix
JP7031934B2 (en) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ Separation matrix
EP3455243B1 (en) 2016-05-11 2021-03-24 Cytiva BioProcess R&D AB Separation matrix
CN109475627B (en) 2016-05-26 2023-01-06 齐鲁普吉湾生物治疗公司 Antibody mixtures
EP3464375A2 (en) 2016-06-02 2019-04-10 Novartis AG Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
WO2017212071A1 (en) 2016-06-10 2017-12-14 Lonza Ltd Method for stabilizing proteins
EP4410378A3 (en) 2016-07-01 2024-10-09 Resolve Therapeutics, LLC Optimized binuclease fusions and methods
MX2018015853A (en) 2016-07-14 2019-08-21 Genmab As Multispecific antibodies against cd40 and cd137.
AU2017295886C1 (en) 2016-07-15 2024-05-16 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
AU2017298535B2 (en) * 2016-07-19 2020-12-10 Ibentrus, Inc. Bispecific proteins and methods for preparing same
TW202508628A (en) 2016-07-28 2025-03-01 瑞士商諾華公司 Combination therapies of chimeric antigen receptors and pd-1 inhibitors
JP2019527696A (en) 2016-08-01 2019-10-03 ノバルティス アーゲー Treatment of cancer using chimeric antigen receptors in combination with inhibitors of pro-M2 macrophage molecules
CN109790215B (en) 2016-09-29 2023-06-30 北京韩美药品有限公司 Heterodimeric immunoglobulin constructs and methods for their preparation
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
CN110225927B (en) 2016-10-07 2024-01-12 诺华股份有限公司 Chimeric Antigen Receptors for Cancer Treatment
CA3043652A1 (en) * 2016-11-18 2018-05-24 Beijing Hanmi Pharmaceutical Co., Ltd. Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
WO2018098376A1 (en) 2016-11-22 2018-05-31 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
EP4043485A1 (en) 2017-01-26 2022-08-17 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
WO2018158719A1 (en) 2017-03-02 2018-09-07 Novartis Ag Engineered heterodimeric proteins
EP4527854A3 (en) 2017-03-09 2025-06-25 Genmab A/S Antibodies against pd-l1
JP7330942B2 (en) 2017-03-31 2023-08-22 ジェンマブ ホールディング ビー．ブイ． Bispecific Anti-CD37 Antibodies, Monoclonal Anti-CD37 Antibodies, and Methods of Using Them
CA3058009A1 (en) 2017-04-01 2018-10-04 Beijing Hanmi Pharm. Co., Ltd. Anti-pd-l1/anti-pd-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof
AU2018249493A1 (en) 2017-04-03 2019-09-19 Oncxerna Therapeutics, Inc. Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
UY37758A (en) 2017-06-12 2019-01-31 Novartis Ag METHOD OF MANUFACTURING OF BIESPECTIFIC ANTIBODIES, BISPECTIFIC ANTIBODIES AND THERAPEUTIC USE OF SUCH ANTIBODIES
KR102324568B1 (en) 2017-06-21 2021-11-10 길리애드 사이언시즈, 인코포레이티드 Multispecific antibodies targeting HIV gp120 and CD3
MA49457A (en) 2017-06-22 2020-04-29 Novartis Ag CD73 BINDING ANTIBODY MOLECULES AND THEIR USES
AU2018292618A1 (en) 2017-06-27 2019-12-19 Novartis Ag Dosage regimens for anti-TIM-3 antibodies and uses thereof
BR112020000719A2 (en) 2017-07-11 2020-07-14 Compass Therapeutics Llc agonist antibodies that bind human cd137 and their uses
AU2018302283B2 (en) 2017-07-20 2025-07-10 Novartis Ag Dosage regimens of anti-LAG-3 antibodies and uses thereof
US11077059B2 (en) 2017-07-25 2021-08-03 Elektrofi, Inc. Electrospraying formation of particles including agents
CN111406067B (en) 2017-08-04 2022-11-08 健玛保 Binding agents that bind to PD-L1 and CD137 and uses thereof
MX2020002070A (en) 2017-08-22 2020-03-24 Sanabio Llc Soluble interferon receptors and uses thereof.
MX2020003497A (en) 2017-10-20 2020-07-22 Hoffmann La Roche Method for generating multispecific antibodies from monospecific antibodies.
AU2018358883B2 (en) 2017-10-30 2025-09-25 F. Hoffmann-La Roche Ag Method for in vivo generation of multispecific antibodies from monospecific antibodies
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
MX2020003472A (en) 2017-11-01 2020-08-03 Chugai Pharmaceutical Co Ltd VARIANT AND ISOFORM OF ANTIBODIES WITH REDUCED BIOLOGICAL ACTIVITY.
BR112020008888A2 (en) 2017-11-16 2020-10-20 Novartis Ag combination therapies
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3746116A1 (en) 2018-01-31 2020-12-09 Novartis AG Combination therapy using a chimeric antigen receptor
WO2019153200A1 (en) 2018-02-08 2019-08-15 北京韩美药品有限公司 Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody in heterodimeric form and preparation thereof
WO2019154349A1 (en) 2018-02-11 2019-08-15 北京韩美药品有限公司 Anti-pd-1/anti-vegf natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof
CR20250348A (en) 2018-03-12 2025-09-23 Genmab As ANTIBODIES JOINING 5T4 (Divisional 2020-463)
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
CN120285175A (en) 2018-05-16 2025-07-11 詹森生物科技公司 Methods for treating cancer and enhancing the efficacy of T cell redirecting therapeutics
EP3797120A1 (en) 2018-05-21 2021-03-31 Compass Therapeutics LLC Compositions and methods for enhancing the killing of target cells by nk cells
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
CN108640997A (en) * 2018-05-22 2018-10-12 蔡毓旻 A kind of bispecific antibody
WO2019226969A1 (en) 2018-05-24 2019-11-28 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
BR112020024351A2 (en) 2018-06-01 2021-02-23 Novartis Ag binding molecules against bcma and uses thereof
TWI848953B (en) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 Multi-specific binding proteins for cancer treatment
CA3100724A1 (en) 2018-06-13 2019-12-19 Novartis Ag B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
SG11202012712YA (en) 2018-06-19 2021-01-28 Atarga Llc Antibody molecules to complement component 5 and uses thereof
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
AR116109A1 (en) 2018-07-10 2021-03-31 Novartis Ag DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
KR20210116429A (en) 2018-10-04 2021-09-27 젠맵 홀딩 비.브이. Pharmaceutical Compositions Comprising Bispecific Anti-CD37 Antibodies
CN113454111A (en) 2018-11-06 2021-09-28 健玛保 Antibody formulation
WO2020102387A1 (en) 2018-11-13 2020-05-22 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
TWI874341B (en) 2018-12-18 2025-03-01 美商健生生物科技公司 Methods of producing heterodimeric antibodies
KR20210106483A (en) 2018-12-20 2021-08-30 노파르티스 아게 Extended low-dose regimen for MDM2 inhibitors
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CN113329759A (en) * 2019-01-07 2021-08-31 沙塔克实验室有限公司 Heterodimeric proteins for modulating gamma delta T cells
TWI852977B (en) 2019-01-10 2024-08-21 美商健生生物科技公司 Prostate neoantigens and their uses
JP2022523510A (en) 2019-01-31 2022-04-25 エレクトロフィ，インコーポレイテッド Particle formation and morphological structure
BR112021015672A2 (en) 2019-02-15 2021-10-05 Novartis Ag 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
US20220144807A1 (en) 2019-02-15 2022-05-12 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
SG11202109061YA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to t cell related cancer cells and uses thereof
US20220088075A1 (en) 2019-02-22 2022-03-24 The Trustees Of The University Of Pennsylvania Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
JP2022527790A (en) 2019-03-29 2022-06-06 アターガ，エルエルシー Anti-FGF23 antibody molecule
EP3956343A1 (en) * 2019-04-16 2022-02-23 Bachem Holding AG Manufacture of disulfide bonded peptides
KR20220010743A (en) 2019-05-21 2022-01-26 노파르티스 아게 Trispecific binding molecules to BCMA and uses thereof
CN113874398B (en) 2019-05-21 2025-08-01 诺华股份有限公司 CD19 binding molecules and uses thereof
WO2020236797A1 (en) 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
SG11202112926YA (en) 2019-05-30 2021-12-30 Amgen Inc Engineering the hinge region to drive antibody dimerization
BR112022001368A2 (en) 2019-07-26 2022-05-24 Janssen Biotech Inc Proteins comprising kallikrein-related peptidase 2 antigen-binding domains and their uses
GB201910900D0 (en) * 2019-07-31 2019-09-11 Scancell Ltd Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
MX2022001882A (en) 2019-08-12 2022-05-30 Aptevo Res & Development Llc 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40.
EP4013783A1 (en) 2019-08-15 2022-06-22 Janssen Biotech, Inc. Materials and methods for improved single chain variable fragments
EP4028424A1 (en) 2019-09-12 2022-07-20 Genmab A/S Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer
AU2020344675A1 (en) 2019-09-13 2022-03-31 Elektrofi, Inc. Compositions and methods for the delivery of therapeutic biologics for treatment of disease
MX2022004766A (en) 2019-10-21 2022-05-16 Novartis Ag Combination therapies with venetoclax and tim-3 inhibitors.
JP2022553306A (en) 2019-10-21 2022-12-22 ノバルティス アーゲー TIM-3 inhibitors and uses thereof
CN114761037A (en) 2019-11-26 2022-07-15 诺华股份有限公司 Chimeric antigen receptor binding to BCMA and CD19 and uses thereof
EP4076660A1 (en) 2019-12-20 2022-10-26 Novartis AG Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
EP4084823A4 (en) 2020-01-03 2024-05-15 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
TW202140037A (en) 2020-01-17 2021-11-01 瑞士商諾華公司 Combination therapies
CN115298322A (en) 2020-01-17 2022-11-04 贝克顿迪金森公司 Methods and compositions for single-cell secretomics
BR112022014574A2 (en) * 2020-01-23 2022-09-27 Adagene Ag HETERODIMERIC PROTEIN, ACTIVABLE ANTIBODY, ONE OR MORE NUCLEIC ACIDS, VECTOR, HOST CELL, PHARMACEUTICAL COMPOSITION AND METHODS FOR PREPARING A HETERODIMERIC PROTEIN OR AN ACTIVABLE ANTIBODY AND TO TREAT A DISEASE
KR20220144377A (en) 2020-01-30 2022-10-26 우모자 바이오파마 인코포레이티드 Bispecific transduction promoter
WO2021155916A1 (en) 2020-02-04 2021-08-12 BioNTech SE Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
CN115298193A (en) 2020-02-05 2022-11-04 伊莱利利公司 Peptide synthesizer of series resin reactor
TW202144389A (en) 2020-02-14 2021-12-01 美商健生生物科技公司 Neoantigens expressed in multiple myeloma and their uses
TW202144388A (en) 2020-02-14 2021-12-01 美商健生生物科技公司 Neoantigens expressed in ovarian cancer and their uses
IL295878A (en) 2020-02-27 2022-10-01 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
JP2023517660A (en) 2020-03-13 2023-04-26 ヤンセン バイオテツク，インコーポレーテツド Materials and methods for binding to Siglec3/CD33
KR20220154757A (en) 2020-03-18 2022-11-22 젠맵 에이/에스 Antibodies that bind to B7H4
JP2023520773A (en) 2020-03-27 2023-05-19 ノバルティス アーゲー Bispecific combination therapy for treating proliferative and autoimmune diseases
EP4135841A1 (en) 2020-04-15 2023-02-22 Voyager Therapeutics, Inc. Tau binding compounds
JP2023522627A (en) 2020-04-17 2023-05-31 エレクトロフィ，インコーポレイテッド Method of forming particles by continuous droplet formation and dehydration
MX2022013797A (en) 2020-05-08 2022-11-30 Genmab As Bispecific antibodies against cd3 and cd20.
PH12022500023A1 (en) 2020-05-27 2024-03-11 Janssen Biotech Inc Proteins comprising cd3 antigen binding domains and uses thereof
JP2023531676A (en) 2020-06-23 2023-07-25 ノバルティス アーゲー Dosing Regimens Containing 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives
PH12023550015A1 (en) 2020-07-16 2024-03-11 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
WO2022024024A2 (en) 2020-07-29 2022-02-03 Janssen Biotech, Inc. Proteins comprising hla-g antigen binding domains and their uses
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2022029011A1 (en) 2020-08-06 2022-02-10 BioNTech SE Binding agents for coronavirus s protein
CA3191710A1 (en) 2020-08-20 2022-02-24 Amgen Inc. Antigen binding proteins with non-canonical disulfide in fab region
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4204021A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
AU2021341509A1 (en) 2020-09-10 2023-04-13 Genmab A/S Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
JP2023541860A (en) 2020-09-10 2023-10-04 ジェンマブ エー／エス Bispecific antibodies against CD3 and CD20 in combination therapy to treat diffuse large B-cell lymphoma
KR20230066392A (en) 2020-09-10 2023-05-15 젠맵 에이/에스 Bispecific antibodies to CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma
EP4210746A1 (en) 2020-09-10 2023-07-19 Genmab A/S Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
AU2021339954A1 (en) 2020-09-10 2023-04-13 Genmab A/S Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
WO2022053657A1 (en) 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
CN116194570A (en) * 2020-09-22 2023-05-30 百时美施贵宝公司 Methods for producing therapeutic proteins
MX2023003749A (en) 2020-10-02 2023-04-24 Genmab As Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3.
EP4225786A2 (en) 2020-10-07 2023-08-16 Amgen Inc. Rational selection of building blocks for the assembly of multispecific antibodies
KR20230086765A (en) 2020-10-13 2023-06-15 얀센 바이오테크 인코포레이티드 Bio-engineered T cell mediated immunity, substances and other methods for modulating clusters of differentiation IV and/or VIII
EP4229086A1 (en) 2020-10-15 2023-08-23 UCB Biopharma SRL Binding molecules that multimerise cd45
AU2021363766A1 (en) 2020-10-22 2023-06-15 Janssen Biotech, Inc. Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses
CN116472288A (en) 2020-11-06 2023-07-21 诺华股份有限公司 Antibody Fc variant
CN116390933A (en) 2020-11-06 2023-07-04 诺华股份有限公司 Combination therapy of anti-CD19 and B-cell targeting agents for the treatment of B-cell malignancies
JP2023548529A (en) 2020-11-06 2023-11-17 ノバルティス アーゲー CD19 binding molecules and uses thereof
AU2021379598A1 (en) 2020-11-10 2023-06-08 Amgen Inc. Novel linkers of multispecific antigen binding domains
AU2021378316A1 (en) 2020-11-13 2023-06-01 Novartis Ag Combination therapies with chimeric antigen receptor (car)-expressing cells
IL303328A (en) 2020-12-01 2023-07-01 Aptevo Res & Development Llc CD3-binding bispecific and heterodimeric antibodies to PSMA
WO2022162569A1 (en) 2021-01-29 2022-08-04 Novartis Ag Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
AU2022242125A1 (en) 2021-03-24 2023-11-09 Janssen Biotech, Inc. Proteins comprising cd3 antigen binding domains and uses thereof
CA3214259A1 (en) 2021-03-24 2022-09-29 Janssen Biotech, Inc. Antibody targeting cd22 and cd79b
TW202304979A (en) 2021-04-07 2023-02-01 瑞士商諾華公司 USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
BR112023021089A2 (en) 2021-05-07 2023-12-12 Genmab As PHARMACEUTICAL COMPOSITION, METHOD FOR TREATING A DISEASE, METHOD FOR TREATING CANCER IN AN INDIVIDUAL, USE OF THE PHARMACEUTICAL COMPOSITION, UNIT DOSAGE FORM, KIT OF PARTS, AND, METHOD FOR PREPARING A PHARMACEUTICAL COMPOSITION
AR125874A1 (en) 2021-05-18 2023-08-23 Novartis Ag COMBINATION THERAPIES
WO2022256563A1 (en) 2021-06-04 2022-12-08 Amgen Inc. Anti-ccr8 antibodies and uses thereof
WO2022263357A1 (en) 2021-06-14 2022-12-22 Argenx Iip Bv Anti-il-9 antibodies and methods of use thereof
IL309319A (en) 2021-06-21 2024-02-01 Genmab As Combination dosage regime of cd137 and pd-l1 binding agents
TW202328193A (en) 2021-09-13 2023-07-16 美商健生生物科技公司 Cd33 x vδ2 multispecific antibodies for the treatment of cancer
US20250223376A1 (en) 2021-09-20 2025-07-10 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
US20250019455A1 (en) 2021-09-24 2025-01-16 Pharmaceutica Nv Proteins comprising cd20 binding domains, and uses thereof
AU2022361691A1 (en) 2021-10-08 2024-03-28 Genmab A/S Antibodies binding to cd30 and cd3
JP2024540054A (en) 2021-11-03 2024-10-31 ヤンセン バイオテツク，インコーポレーテツド Methods for Treating Cancer and Improving the Efficacy of BCMAxCD3 Bispecific Antibodies - Patent application
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
KR20240111783A (en) 2021-11-22 2024-07-17 얀센 바이오테크 인코포레이티드 Compositions Comprising Enhanced Multispecific Binding Agents for Immune Responses
CA3243347A1 (en) 2022-01-28 2023-08-03 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
MX2024008833A (en) 2022-01-28 2024-07-25 Genmab As Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma.
TW202342548A (en) 2022-02-07 2023-11-01 美商威特拉公司 Anti-idiotype antibody molecules and uses thereof
WO2023174521A1 (en) 2022-03-15 2023-09-21 Genmab A/S Binding agents binding to epcam and cd137
CN118922448A (en) 2022-03-22 2024-11-08 莫佛塞斯公司 CD3 specific deimmunized antibodies
US20250304689A1 (en) 2022-04-13 2025-10-02 Genmab A/S Bispecific antibodies against cd3 and cd20
CR20240455A (en) 2022-04-26 2024-12-20 Novartis Ag Multispecific antibodies targeting il-13 and il-18
US20250295809A1 (en) 2022-05-13 2025-09-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
EP4565597A2 (en) 2022-08-03 2025-06-11 Voyager Therapeutics, Inc. Compositions and methods for crossing the blood brain barrier
CA3266790A1 (en) 2022-09-15 2024-03-21 Voyager Therapeutics, Inc. Tau binding compounds
US20240174761A1 (en) 2022-11-02 2024-05-30 Genmab A/S Bispecific antibodies against cd3 and cd20 for treating richter's syndrome
CN120282797A (en) 2022-11-02 2025-07-08 詹森生物科技公司 Methods of treating cancer
JP2026500710A (en) * 2022-12-27 2026-01-08 メルス ナムローゼ フェンノートシャップ Methods for producing bispecific proteins
WO2024168061A2 (en) 2023-02-07 2024-08-15 Ayan Therapeutics Inc. Antibody molecules binding to sars-cov-2
CN121399155A (en) 2023-03-17 2026-01-23 奥西托普制药有限公司 Antiphosphocholine antibodies and their usage
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
CN121240884A (en) 2023-04-05 2025-12-30 根马布股份公司 Pharmaceutical compositions containing antibodies that bind to CD30 and CD3
TW202506702A (en) * 2023-04-07 2025-02-16 美商輝瑞股份有限公司 Method of forming multi-specific antibodies from homodimer antibodies and pharmaceutical product including multi-specific antibodies thus obtained
CN121311504A (en) 2023-04-13 2026-01-09 金麦安博股份有限公司 Methods of treating lymphomas with bispecific antibodies directed against CD3 and CD20
AR133071A1 (en) 2023-06-30 2025-08-20 Genmab As ANTIBODIES THAT BIND TO FIBROBLAST ACTIVATION PROTEIN a AND DEATH RECEPTOR 4
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
TW202523349A (en) 2023-08-07 2025-06-16 美商健生生物科技公司 Gucy2c antibodies and uses thereof
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025133707A1 (en) 2023-12-19 2025-06-26 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
US20250206816A1 (en) * 2023-12-26 2025-06-26 Medicovestor, Inc. METHODS OF CROSSLINKING IgG
US12121587B1 (en) 2023-12-26 2024-10-22 Medicovestor, Inc. Dimeric antibodies
US12116410B1 (en) * 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
US12258396B1 (en) 2024-02-02 2025-03-25 Medicovestor, Inc. Methods of using immunotherapeutics that bind folate receptor alpha
US12240900B1 (en) 2024-02-02 2025-03-04 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode antibodies and other proteins that bind folate receptor alpha
US12378314B1 (en) 2024-02-02 2025-08-05 Medicovestor, Inc. Proteins that bind folate receptor alpha including fully-human antibodies
US20260041768A1 (en) 2024-05-03 2026-02-12 Janssen Biotech, Inc. Methods for treating multiple myeloma with car-t cells and bispecific antibodies
WO2025231372A2 (en) 2024-05-03 2025-11-06 Janssen Biotech, Inc. Methods for treating multiple myeloma with car-t cells and bispecific antibodies

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2592668A (en) 1948-09-08 1952-04-15 Dufour Leon Locking mechanism for a differential
US5292668A (en) * 1981-12-21 1994-03-08 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69127627T2 (en) 1990-08-29 1998-02-19 Genpharm Int Production and Use Non-human transgene heterologous antibodies for production
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
CA2113113A1 (en) 1991-07-08 1993-01-21 Simon W. Kantor Thermotropic liquid crystal segmented block copolymer
SE9201331D0 (en) * 1992-04-28 1992-04-28 Hightech Receptor C O Active PROTEIN L AND HYBRID PROTEINS THEREOF
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int Transgenic non-human animals capable of producing heterologous antibodies
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
KR970029803A (en) 1995-11-03 1997-06-26 김광호 Precharge Circuit of Semiconductor Memory Device
EP0912612B1 (en) 1996-07-25 2003-10-01 GSF - Forschungszentrum für Umwelt und Gesundheit, GmbH Simplified production of bispecific antibody fragments
US20040038894A1 (en) 1996-12-31 2004-02-26 Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) Compounds for modulating cell negative regulations and biological applications thereof
ATE299938T1 (en) * 1997-05-02 2005-08-15 Genentech Inc A METHOD FOR PRODUCING MULTI-SPECIFIC ANTIBODIES THAT POSSESS HETEROMULTIMER AND COMMON COMPONENTS
JP2002512776A (en) 1998-04-28 2002-05-08 スミスクライン・ビーチャム・コーポレイション Monoclonal antibodies with reduced immunogenicity
US6528286B1 (en) * 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
DE19859115A1 (en) 1998-09-25 2000-03-30 Horst Lindhofer Use of delayed tumor cells in combination with intact antibodies for immunization
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1150918B1 (en) 1999-02-03 2004-09-15 Biosante Pharmaceuticals, Inc. Method of manufacturing therapeutic calcium phosphate particles
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
JP2003516718A (en) 1999-07-29 2003-05-20 メダレックス インク Human monoclonal antibody against HER2 / neu
EP1944317A3 (en) * 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP4298498B2 (en) 2001-06-13 2009-07-22 ゲンマブ エー／エス Human monoclonal antibody against epidermal growth factor receptor (EGFR)
US6833441B2 (en) * 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
ES2524694T3 (en) 2002-10-17 2014-12-11 Genmab A/S Human monoclonal antibodies against CD20
CN1748143A (en) * 2002-12-16 2006-03-15 健泰科生物技术公司 Transgenic mice expressing human cd20 and/or cd16
WO2005000898A2 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
EP1693386A4 (en) 2003-11-04 2008-12-31 Chugai Pharmaceutical Co Ltd METHOD FOR PRODUCING ANTIBODIES
US20050136051A1 (en) 2003-12-22 2005-06-23 Bernard Scallon Methods for generating multimeric molecules
US8772013B2 (en) 2004-02-02 2014-07-08 Engeneic Molecular Delivery Pty Ltd Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
US7537930B2 (en) * 2004-07-23 2009-05-26 Immunomedics, Inc. Mammalian cell lines for increasing longevity and protein yield from a cell culture
US20060074225A1 (en) * 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
US8911726B2 (en) 2004-09-22 2014-12-16 Kyowa Hakko Kirin Co., Ltd Stabilized human Igg4 antibodies
WO2006047340A2 (en) 2004-10-22 2006-05-04 Amgen Inc. Methods for refolding of recombinant antibodies
IL296666A (en) 2005-03-23 2022-11-01 Genmab As Antibodies against cd38 for treatment of multiple myeloma
TWI671403B (en) 2005-03-31 2019-09-11 中外製藥股份有限公司 Method for controlling controlled assembly of polypeptide
KR20080090406A (en) 2005-11-28 2008-10-08 젠맵 에이/에스 Recombinant monovalent antibody and preparation method thereof
US9181344B2 (en) 2005-12-15 2015-11-10 Genmab A/S Use of effector-function-deficient antibodies for treatment of auto-immune diseases
GB0601513D0 (en) * 2006-01-25 2006-03-08 Univ Erasmus Medical Ct Binding molecules 3
KR20080104343A (en) 2006-03-03 2008-12-02 엘란 파마슈티칼스, 인크. How to treat inflammatory and autoimmune diseases with natalizumab
PT1999154E (en) 2006-03-24 2013-01-24 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2007147901A1 (en) * 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
CA2681974C (en) * 2007-03-29 2019-12-31 Genmab A/S Bispecific antibodies and methods for production thereof
EP2144628B1 (en) * 2007-05-08 2012-10-17 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
JP5570974B2 (en) 2007-05-31 2014-08-13 ゲンマブ エー／エス Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
EP2666787B1 (en) 2007-05-31 2022-02-09 Genmab A/S STABLE IgG4 ANTIBODIES
US20090042253A1 (en) * 2007-08-09 2009-02-12 Wyeth Use of perfusion to enhance production of fed-batch cell culture in bioreactors
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
US8318899B2 (en) 2008-01-24 2012-11-27 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Lytic domain fusion constructs and methods of making and using same
TWI472339B (en) * 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
PL2282773T3 (en) 2008-05-02 2014-08-29 Seattle Genetics Inc Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
CA3053156A1 (en) * 2008-12-03 2010-06-10 Genmab A/S Antibody variants having modifications in the constant region
EP3444611A1 (en) * 2009-04-23 2019-02-20 Siemens Healthcare Diagnostics Inc. Monomeric and dimeric forms of adiponectin receptor fragments and methods of use
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
EP2975051B1 (en) 2009-06-26 2021-04-14 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
JP2013507926A (en) * 2009-10-14 2013-03-07 メリマック ファーマシューティカルズ インコーポレーティッド Bispecific binding agents targeting IGF-1R and ErbB3 signaling and uses thereof
LT2560993T (en) 2010-04-20 2024-10-10 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
BR112012027001A2 (en) * 2010-04-23 2016-07-19 Genentech Inc heteromultimeric protein production
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
MX352929B (en) 2010-11-05 2017-12-13 Zymeworks Inc DESIGN OF STABLE HETERODIMERIC ANTIBODIES WITH MUTATIONS IN THE DOMAIN Fc.
RU2013140685A (en) * 2011-02-04 2015-03-10 Дженентек, Инк. OPTIONS Fc, METHODS FOR PRODUCING THEM
CA2828811C (en) 2011-03-03 2021-09-21 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
WO2012143524A2 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
US20140170148A1 (en) 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2
PT2771364T (en) 2011-10-27 2019-09-10 Genmab As Production of heterodimeric proteins
SMT201800624T1 (en) 2012-11-21 2019-01-11 Janssen Biotech Inc Bispecific egfr/c-met antibodies
KR20220156667A (en) 2013-01-10 2022-11-25 젠맵 비. 브이 Human igg1 fc region variants and uses thereof

Also Published As

Publication number Publication date
IL232022B (en) 2021-05-31
ES2739808T3 (en) 2020-02-04
AU2020200496B2 (en) 2021-12-09
IN2014CN03887A (en) 2015-10-16
AU2012328322A1 (en) 2014-06-12
CN104114579A (en) 2014-10-22
SG10201805291TA (en) 2018-08-30
WO2013060867A2 (en) 2013-05-02
US20230227495A1 (en) 2023-07-20
JP6797169B2 (en) 2020-12-09
US11492371B2 (en) 2022-11-08
EP3674320A3 (en) 2020-08-12
US20140303356A1 (en) 2014-10-09
IL282393A (en) 2021-06-30
HRP20191337T1 (en) 2019-10-18
US10344050B2 (en) 2019-07-09
KR102049803B1 (en) 2019-11-29
BR112014010023B1 (en) 2023-11-21
HUE044633T2 (en) 2019-11-28
CN118290588A (en) 2024-07-05
DK2771364T3 (en) 2019-08-19
EP2771364A2 (en) 2014-09-03
KR20140091014A (en) 2014-07-18
JP6475017B2 (en) 2019-02-27
CN110964115A (en) 2020-04-07
HK1201540A1 (en) 2015-09-04
US20200048304A1 (en) 2020-02-13
AU2017261467B2 (en) 2019-10-24
RS59166B1 (en) 2019-10-31
EP3674320A2 (en) 2020-07-01
PL2771364T3 (en) 2020-01-31
SI2771364T1 (en) 2019-10-30
WO2013060867A3 (en) 2013-06-20
CN110964115B (en) 2024-03-12
BR112014010023A2 (en) 2017-04-25
PT2771364T (en) 2019-09-10
AU2020200496A1 (en) 2020-02-13
SG11201401422VA (en) 2014-09-26
JP2019065014A (en) 2019-04-25
AU2017261467A1 (en) 2017-11-30
EP2771364B1 (en) 2019-05-22
JP2014530891A (en) 2014-11-20
LT2771364T (en) 2019-09-10
AU2017261467B9 (en) 2019-11-14
CN104114579B (en) 2020-01-24
IL282393B (en) 2022-02-01

Similar Documents

Publication Publication Date Title
IL282393B (en) Production of heterodimeric proteins
PL2706867T3 (en) Method of making structured protein compositions
ZA201208533B (en) Production of solluble protein solutions from pulses
SG11201504694VA (en) Method for producing a recombinant protein of interest
ZA201502519B (en) Production of particles
SG11201403814RA (en) Production of recombinant proteins with simple glycoforms
SG11201402979PA (en) Biotechnological production of 3-hydroxyisobutyric acid
GB2494153B (en) Selection of codecs
GB201120696D0 (en) Production of mono-cystalline silicon
HUP1100510A2 (en) Production of biogas from protein-rich material
SG10201606218WA (en) Purified Proteins
BR112014023176A2 (en) Methods of producing a recombinant protein
SG2014002240A (en) Production of paraxylene
EP2889368A4 (en) ACCELERATOR OF PROTEIN PRODUCTION
GB201004096D0 (en) Production of polyhydroalkanoates
SG10201602874VA (en) Protein production method
GB201120550D0 (en) Photobioreactor
GB201220155D0 (en) Method of manufacture
IL238545B (en) Plants for production of therapeutic proteins
HUP1200171A1 (en) Methods for the production of polypeptides
EP2737065A4 (en) Protein production method
EP2684869A4 (en) Preparation of 3-mercaptopropionates
EP2768941A4 (en) Photobioreactor
EP2855401A4 (en) Production of bn-composite materials
HK40032845A (en) Production of heterodimeric proteins

Legal Events

Date Code Title Description
FF Patent granted